Stay updated on Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Results section updated with data on dose-limiting toxicities, timing, and RECIST responses. Exploratory biomarker endpoints were removed.
    Difference
    3%
    Check dated 2026-02-18T04:24:21.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed Revision: v3.4.1 along with the funding/operating-status notice. There are no visible changes to the study details or results.
    Difference
    0.5%
    Check dated 2026-02-11T02:32:19.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Administrative notices were added: a government funding lapse notice and an update to version 3.4.1. The prior version 3.4.0 was removed.
    Difference
    0.5%
    Check dated 2026-02-03T23:25:13.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary toggle and updated footer/version details to show 'Last Update Submitted that Met QC Criteria' and Revision: v3.4.0. Removed older wording/capitalization variants ('Last Update Submitted that met QC Criteria', 'No FEAR Act data') and the previous revision label (v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T00:17:16.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision: v3.3.4 replaces the previous Revision: v3.3.3 on the page header/footer. This appears to be a minor system update and does not affect trial details.
    Difference
    0.1%
    Check dated 2026-01-13T17:43:16.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page footer now shows a new revision label Revision: v3.3.3. The items HHS Vulnerability Disclosure and the previous Revision: v3.3.2 have been removed.
    Difference
    0.1%
    Check dated 2025-12-23T08:50:10.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.